|05/10/16||StemCells, Inc. to Report 12-Month Cohort I Data from its Phase II Pathway Study|
|NEWARK, Calif., May 10, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM), a leading stem cell company developing novel cell-based therapeutics for the treatment of serious central nervous system diseases, today announced that it will be presenting top line 12-month data from Cohort I of its Pathway™ Study later this month as part of the Company’s first quarter 2016 analyst call. The Company is planning to then release detailed final data on Cohort I at a scientific venue in June.
The ... |
|05/06/16||StemCells, Inc. Announces 1-for-12 Reverse Stock Split|
|NEWARK, Calif., May 06, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM), announced today that at its annual stockholders meeting held on May 5, 2016, the Company's stockholders voted to approve a reverse stock split of the Company's common stock at a ratio of 1-for-12. Trading of the Company's common stock on the NASDAQ Capital Market will continue, on a split-adjusted basis, with the opening of the markets on Monday, May 9, 2016, under the existing trading symbol "STEM" and a new CUSI... |
|04/27/16||StemCells, Inc. to Participate in the 3rd Annual Growth Capital Expo MicroCap Investor Conference in Las Vegas, NV|
|NEWARK, Calif., April 27, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that management will make a presentation on the Company's programs, pipeline and operations at the 3rd Annual Growth Capital Expo MicroCap Investor Conference, held May 3 – 5, 2016 at Caesars Palace in Las Vegas, NV. The Company will be presenting at 11:00 a.m. Pacific Daylight Time on Wednesday, May 4.
A live webcast of the presentation will be available through the Company's corporate website:... |
|04/18/16||StemCells, Inc. Presents Interim Results from its Phase II Pathway Study in Chronic Cervical Spinal Cord Injury at ASIA Annual Meeting|
|Final Results for the First Six Patients to be Released Later this Quarter
NEWARK, Calif., April 18, 2016 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of central nervous system disorders, announced today that Dr. Stephen Huhn, the Company’s Chief Medical Officer and VP of Clinical Research, presented additional details on its ongoing Phase II Pathway™ Study of HuCNS-SC cells for the treatment of ... |